Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Celgene Completes Avila Acquisition | Contract Pharma

What are you searching for?

Sign in
Breaking News

Celgene Completes Avila Acquisition

Gains Phase I drug and Avilomics discovery platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Celgene Corp. has completed its acquisition of Avila Therapeutics for $350 million in cash, with as much as $575 million more contingent upon AVL-292 milestones and candidates from Avila’s discovery program.
 
Celgene gains a highly-selective Bruton’s tyrosine kinase inhibitor currently in Phase I development, as well as the Avilomics discovery platform for developing targeted covalent drugs that treat diseases through protein silencing.
 
“The Avilomics research team brings to Celgene an exciting clinical candidate in AVL-292, along with a dynamic platform of protein silencing that has tremendous potential,” said Tom Daniel, M.D., EVP, president of Research and Early Development for Celgene. “We welcome our new colleagues and look forward to the impact that the combined organization will have on the lives of patients receiving our drugs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics